GR1007327B - Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους - Google Patents

Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους

Info

Publication number
GR1007327B
GR1007327B GR20070100514A GR20070100514A GR1007327B GR 1007327 B GR1007327 B GR 1007327B GR 20070100514 A GR20070100514 A GR 20070100514A GR 20070100514 A GR20070100514 A GR 20070100514A GR 1007327 B GR1007327 B GR 1007327B
Authority
GR
Greece
Prior art keywords
peptic ulcer
efficiency
controlling
myeloid cells
trem
Prior art date
Application number
GR20070100514A
Other languages
English (en)
Other versions
GR20070100514A (el
Inventor
Ευαγγελος Γιαμαρελλος-Μπουρμπουλης
Βασιλειος Κουσουλας
Original Assignee
Ευαγγελος Γιαμαρελλος-Μπουρμπουλης
Βασιλειος Κουσουλας
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ευαγγελος Γιαμαρελλος-Μπουρμπουλης, Βασιλειος Κουσουλας filed Critical Ευαγγελος Γιαμαρελλος-Μπουρμπουλης
Priority to GR20070100514A priority Critical patent/GR1007327B/el
Publication of GR20070100514A publication Critical patent/GR20070100514A/el
Publication of GR1007327B publication Critical patent/GR1007327B/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Προτείνεται η χρήση του προσδιορισμού ενός νέου πολυπεπτιδίου του διαλυτού υποδοχέα ενεργοποίησης των μυελοκυττάρων (sTREM-1) στον ορό ασθενών πεπτικό έλκος. Οι ασθενείς θα υποβάλλονται στην εξέτασηπρο και μετά κ πέρας της αγωγής που έλαβαν για την επούλωση του πεπτικού έλκους. Σκοπός της μεθόδου είναι ο έλεγχος της αποτελεσματικότητας της θεραπείας του έλκους και συνεπώς, η αναγκαιότητα ή μη περαιτέρω θεραπευτικής παρέμβασης.
GR20070100514A 2007-08-08 2007-08-08 Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους GR1007327B (el)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20070100514A GR1007327B (el) 2007-08-08 2007-08-08 Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20070100514A GR1007327B (el) 2007-08-08 2007-08-08 Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους

Publications (2)

Publication Number Publication Date
GR20070100514A GR20070100514A (el) 2009-03-17
GR1007327B true GR1007327B (el) 2011-06-27

Family

ID=40481618

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20070100514A GR1007327B (el) 2007-08-08 2007-08-08 Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους

Country Status (1)

Country Link
GR (1) GR1007327B (el)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186636B2 (en) 2017-04-21 2021-11-30 Amgen Inc. Anti-human TREM2 antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081233A1 (en) * 2003-03-10 2004-09-23 Bioxell S.P.A. Diagnostic and prognostic compounds and method
WO2005071408A1 (en) * 2004-01-27 2005-08-04 Bioxell S.P.A. Method of diagnosing infectious disease by measuring the level of soluble trem-1 in a sample
WO2006056492A1 (en) * 2004-11-29 2006-06-01 Bioxell Spa Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081233A1 (en) * 2003-03-10 2004-09-23 Bioxell S.P.A. Diagnostic and prognostic compounds and method
WO2005071408A1 (en) * 2004-01-27 2005-08-04 Bioxell S.P.A. Method of diagnosing infectious disease by measuring the level of soluble trem-1 in a sample
WO2006056492A1 (en) * 2004-11-29 2006-06-01 Bioxell Spa Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Base de données EMBL. Entrée HS417D01B Numéro d'accès D61556; 31 août 1995 FUJIWARA T. ET AL, EMBL NUCLEOTIDE SEQUENCE, XP002008028 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186636B2 (en) 2017-04-21 2021-11-30 Amgen Inc. Anti-human TREM2 antibodies and uses thereof

Also Published As

Publication number Publication date
GR20070100514A (el) 2009-03-17

Similar Documents

Publication Publication Date Title
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
NZ593281A (en) Sparc binding peptides and uses thereof
PH12018500639A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
EA200971053A1 (ru) Способы лечения кожных язв
JP2013523349A5 (el)
MX2010005244A (es) Composiciones y métodos para la terapia y el diagnóstico de influenza.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
IN2012DN06309A (el)
MX353964B (es) Agentes terapeuticos y usos de los mismos.
SG179027A1 (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
PL1778833T3 (pl) Sposoby stosowania komórek regeneracyjnych w celu przyspieszania gojenia się ran
EA201290278A1 (ru) Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
WO2021035222A3 (en) Apparatus for systemic human enhancement from administration of frequency therapy including enhanced stem cell and genetic therapy
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
GR1007327B (el) Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους
Pasek et al. Comparison of the efficacy of topical hyperbaric oxygen therapy alone vs a combination of physical methods including topical hyperbaric oxygen therapy, magnetotherapy, and low‐energy light therapy in the treatment of venous leg ulcers
DK1778834T5 (da) Fremgangsmåder til anvendelse af regenerative celler i behandlingen af renale sygdomme og lidelser
Nör Buonocore memorial lecture
Loder et al. QS59. Pulsed-release Dexamethasone-loaded Microspheres Mitigate Scar Contracture and Adhesions in Composite Tissue Burn Reconstruction
Kim Reducing effect on early stage of the gingivitis by use of vibratory gingival stimulator and the low frequency wave unit

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20110714

ML Lapse due to non-payment of fees

Effective date: 20140305